MBB Public Markets I LLC Acquires New Position in Catalent, Inc. (NYSE:CTLT)

MBB Public Markets I LLC acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 14,020 shares of the company’s stock, valued at approximately $788,000.

A number of other institutional investors have also modified their holdings of CTLT. Thurston Springer Miller Herd & Titak Inc. bought a new position in Catalent in the 2nd quarter worth about $42,000. Mather Group LLC. bought a new position in shares of Catalent in the first quarter valued at approximately $52,000. Longfellow Investment Management Co. LLC boosted its holdings in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares in the last quarter. Finally, Sound Income Strategies LLC boosted its holdings in shares of Catalent by 4,466.7% in the first quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock valued at $77,000 after acquiring an additional 1,340 shares in the last quarter.

Catalent Stock Down 0.8 %

Catalent stock opened at $60.08 on Wednesday. The stock has a market capitalization of $10.87 billion, a PE ratio of -9.85, a price-to-earnings-growth ratio of 2.32 and a beta of 1.15. Catalent, Inc. has a twelve month low of $31.80 and a twelve month high of $61.20. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The company has a 50 day moving average of $59.74 and a 200-day moving average of $57.37.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.23 billion. On average, equities research analysts anticipate that Catalent, Inc. will post 0.85 EPS for the current fiscal year.

Insider Activity

In other news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now directly owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ricky Hopson sold 662 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the sale, the insider now owns 29,974 shares in the company, valued at $1,785,251.44. The disclosure for this sale can be found here. Insiders have sold 15,403 shares of company stock valued at $902,503 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

CTLT has been the subject of several recent analyst reports. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, June 28th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com began coverage on shares of Catalent in a research note on Thursday, September 26th. They issued a “sell” rating on the stock. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Finally, Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. Based on data from MarketBeat.com, Catalent presently has an average rating of “Hold” and a consensus target price of $59.83.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.